INS Webinar Series: The Development of a Novel Spinal Cord Stimulation Therapy

ReachMD Healthcare Image

The live program has concluded.


If you attended, please click on the "Take Post-Test" button to claim your credit. If you did not attend, please stay tuned for the archived version, which will be available soon for on-demand viewing.

Details
  • Overview

    Building on the success of the International Neuromodulation Society’s (INS) inaugural, 10-part CME webinar series, the INS will be launching a new series of educational webinars in 2021 to:
    • keep neuromodulators abreast of the latest therapies and best clinical practices;
    • sustain growth in the field of neuromodulation; and
    • provide a home for our global community until we can meet in person again.

    In March 2021 through early 2022, the INS will host at least 10 monthly CME webinars for both members and non-members alike, with the aim of providing education on the mechanisms of action of the full spectrum of neuromodulation therapies, as well as guidance on patient safety, patient selection, and device selection to optimize treatment outcomes and reduce adverse events – all of which are of paramount importance in the field of neuromodulation. This program, which will feature vagus nerve stimulation in a two-part series of webinars, is providing an opportunity for the global neuromodulation community to connect virtually and earn CME credit when they cannot meet in person.

    TARGET AUDIENCE
    This certified CME activity is designed to provide a learning opportunity for the membership of the INS, as well as non-members, including clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation. The INS consists of over 3,100 members worldwide; of the 70% of members who have reported their specialties, 16% consists of neurological surgeons, and 4.7% of neurologists.

    Please click on Begin Course to access your evaluation and certificate.

    Supported by an educational grant from Nalu Medical.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Describe the process of modeling a new concept and the methods required to refine this concept into a potential therapy.
    • Discuss the demonstration of effectiveness and safety using animal models of pain.
    • Understand the process by which animal data are used to support human clinical neuromodulation trials.
    • Accreditation

      Jointly Provided by Evolve Medical Education, LLC and International Neuromodulation Society.
      This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education, LLC and International Neuromodulation Society. Evolve Medical Education; LLC is accredited by the ACCME to provide continuing medical education for physicians. 

      Evolve Medical Education designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

    • Participation Method

      In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

      Course Viewing Requirements
      Supported Browsers: Internet Explorer 11 for Windows
      Edge (recent versions; Chromium-based) for Windows
      Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
      Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
      Safari (recent versions) for Mac OSX, or iOS

      Hardware Requirements:
      4GB+ RAM Recommended internet speed 5Mbps+

    • Faculty and Disclosures

      Robert M. Levy, MD

      Robert M. Levy, MD

      President
      International Neuromodulation Society 


      Stana Bojanic, BSc, MB BS, FRCS(SN)

      Stana Bojanic, BSc, MB BS, FRCS(SN)

      Consultant Neurosurgeon and Spinal Surgeon
      Oxford University Hospitals Trust and the Manor Hospital


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

      The following faculty/staff members have the following financial relationships with commercial interests:

      Robert M. Levy, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Shareholder: Stock options from Nalu and Saluda Medical obtained prior to 2019, and not exercisable through the duration as my term as INS President, and Editor-in-Chief of the journal, Neuromodulation Technology at the Neural Interface.

      Stana Bojanic, BSc, MB BS, FRCS(SN), has no financial relationships with commercial interests.

      James Makous, PhD has had a financial agreement of affiliation during the past year with the following commercial interest in the form of Consultant: Nalu Medical, EBT Medical; and Stock Shareholder: Nalu Medical

      Ganesan Baranidharan, MD, MBBS, FRCA, FFPMRCA, PG Dip (anaes) has had a financial agreement or affiliation during the past year with the following commercial interest in the forms of Consultant for: Abbott, Nevro, Mainstay Medical, Nalu Medical, Stryker, Medtronic. Grants/Research: Abbott, Boston Scientific, and Mainstay Medical. Speaker: Stryker, Abbott, Mainstay Medical, Boston Scientific, Nalu Medical. Shareholder: Nalu Medical.

      Paul Verrills, MBBS FAFMM GDMM (Hons) MM (Pain Medicine) FIPP AMA(M) has had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant for: Abbott, Saluda, Biotronik, Nevro, Nalu Medical. Grants/Research: Abbott, Nevro, Nalu Medical. Speaker: Abbott, Nalu. Shareholder: Nalu Medical.

      The Evolve staff/planners, INS staff/planner, and Kenes Group planners have no financial relationships with commercial interests.
      Stana Bojanic, MD, peer reviewer, has no financial relationships with commercial interests.

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindica­tions, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, the International Neuromodulation Society, Kenes Group, or Nalu Medical. 

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Expiration Date:

    1.50 credits
    Completing the pre-test is required to access this content.
    Completing the pre-survey is required to view this content.

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    Register

    We're glad to see you're enjoying Evolve Medical Education…
    but how about a more personalized experience?

    Register for free